查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046352

阿茲海默症生物標記市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、檢測技術、最終用戶、地區和競爭格局分類，2021-2031年

Alzheimers Disease Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Detection Technique, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球阿茲海默症生物標記市場預計將從 2025 年的 9.1 億美元成長到 2031 年的 14.3 億美元，複合年成長率為 7.82%。

這些生物標記作為可量化的生物學指標，可透過腦脊髓液、血漿或影像學技術進行檢測，有助於發現諸如BETA-澱粉樣蛋白斑塊和Tau蛋白纏結等病理變化。這一成長趨勢主要受全球人口老化以及臨床上迫切需要早期診斷以最大限度提高新治療方法療效的驅動。此外，非侵入性血液檢測診斷解決方案的快速發展也透過減輕患者負擔和降低傳統腰椎穿刺的侵入性，擴大了市場。

市場概覽
預測期 2027-2031
市場規模：2025年 9.1億美元
市場規模：2031年 14.3億美元
複合年成長率：2026-2031年 7.82%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

然而，該市場面臨許多挑戰，包括診斷檢測的高昂研發成本和保險報銷的不一致性，這限制了價格敏感地區的患者獲取途徑。鑑於該疾病日益普遍，亟需可擴展的診斷干預措施，此經濟障礙尤其令人擔憂。根據阿茲海默症協會估計，到2025年，美國將有720萬65歲及以上的老年人患有老年失智症失智症。發病率的上升凸顯了業界對經濟高效且易於獲取的生物標記平台的迫切需求，以確保患者能夠得到及時的護理和管理。

市場促進因素

疾病修正治療(DMT) 的激增正在從根本上改變市場格局，因為精準的伴隨診斷對於確定患者合格和監測治療至關重要。隨著監管機構核准針對乙型澱粉樣蛋白的新型單株抗體，臨床方案正迅速納入生物標記檢測，以便在治療開始前確認澱粉樣蛋白病理。這種重要性使得診斷不再只是篩檢工具，而是決定藥物可近性的關鍵安全隔離網閘，直接增加了FDA已通過核准的檢測數量。禮來公司在其2024年7月的FDA核准新聞稿中公佈了其3期TRAILBLAZER-ALZ 2試驗的結果，該試驗對於Kisunra的核准至關重要，這便是臨床療效推動這一需求的例證。試驗表明，在確診澱粉樣蛋白和中度Tau蛋白病理的受試者中，該療法可使臨床進展延緩35%，凸顯了能夠檢測這些特定標誌物的診斷平台的重要性。

同時，微創血液生物標記的快速研發和商業化正在消除傳統PET掃描和腦脊髓液分析相關的就診障礙。高性能血漿檢測，特別是磷酸化Tau（p-tau）檢測的引入，使得在基層醫療進行經濟實惠的預先篩檢成為可能，有效識別需要進一步確診的患者。這項技術進步得到了近期數據的支持。 2024年1月發表於美國醫學會（AMA）旗下期刊《美國醫學會神經病學雜誌》（JAMA Neurology）的一篇論文報告稱，一種市售的p-tau217血液檢測在檢測腦內澱粉樣蛋白增多方面達到了96%的診斷準確率。如此高的準確率正在推動該檢測的廣泛應用，鑑於阿茲海默症帶來的巨大經濟負擔，這一點至關重要。阿茲海默症協會預測，到2024年，全美阿茲海默症和其他失智症患者的總費用將達到3,600億美元。

市場挑戰

阻礙市場成長的主要因素是診斷測試開發成本高昂以及保險報銷政策不一致。製造商必須投入巨資進行測試的檢驗和生產，導致價格高昂，限制了許多醫療服務提供者和患者的使用。如果支付方不提供標準化或充足的保險覆蓋，經濟負擔將落在個人或醫療機構身上。這種經濟上的不確定性使得醫療系統不願意將生物標記檢測作為常規標準治療手段，導致檢測量有限，參與企業收入成長停滯不前。

在更廣泛的失智症護理經濟背景下，這種經濟負擔尤其突出，因為資源主要用於長期管理而非診斷。有限的醫療保健資金競爭使得在缺乏保障性支付機制的情況下，引入昂貴的診斷工具變得困難。根據阿茲海默症協會估計，到2024年，65歲及以上失智症患者的醫療、長期照護和臨終關懷服務的總支出預計將達到3,600億美元。如此龐大的現有護理支出使可用預算捉襟見肘，幾乎沒有空間引入新的診斷技術，並直接限制了生物標記市場的擴充性。

市場趨勢

將人工智慧 (AI) 應用於生物標記發現正在革新市場，它能夠從複雜的多模態資料集中檢測出新的病理特徵。與傳統的單一檢測方法不同，AI 演算法能夠分析海量的基因組學、蛋白質組學和影像數據，從而識別臨床症狀出現之前就存在的細微非線性模式。這種能力能夠揭示與疾病檢驗相關的潛在生物學因素，從而加速精準診斷的開發，並改善臨床試驗中的患者分層。為了佐證這項技術融合的潛力，《Premier Science》在 2025 年 1 月發表了報導題為「革新阿茲海默症診斷：AI 工具超越傳統方法」的文​​章，報道了一種新的 AI 模型，該模型透過識別與認知衰退相關的潛在代謝和生理因素，在一個獨立的資料集上實現了近 90% 的預測準確率。

同時，用於遠端監測的數位生物標記的擴充性，正在為可擴展且易於獲取的患者評估建立新的標準。這一趨勢正將診斷數據收集從侵入性臨床環境轉向使用消費級感測器和專用周邊設備進行連續、非侵入性採集，以監測眼動、發聲和行為指標。這些數位設備在檢測臨床前神經退化變化方面尤其有效，而這些變化在間歇性臨床檢測中往往被忽視，從而為大規模人群篩檢提供了一種經濟高效的方法。例如，斯特拉斯克萊德大學於2025年10月宣布，其整合了眼動追蹤技術和機器學習分析的ViewMind Atlas系統能夠以96%的準確率檢測出阿茲海默症相關基因突變的無症狀攜帶者，這充分體現了這些非侵入性方法的高精度。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球阿茲海默症生物標記市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（腦脊髓液生物標記、 乙型澱粉樣蛋白、 Tau蛋白、基因生物標記、載脂蛋白E、血液生物標記、其他）
    • 檢測技術（分子診斷、免疫檢測）
    • 依最終使用者（醫院/診所、診斷檢測機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美阿茲海默症生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲阿茲海默症生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區阿茲海默症生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲阿茲海默症生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美阿茲海默症生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球阿茲海默症生物標記市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Enzo Life Sciences Inc.
  • Thermo Fisher Scientific Inc.
  • AnaSpec Inc.
  • Merck KGaA
  • Cell Signaling Technology Inc.
  • Fujirebio Diagnostics Inc
  • 23andMe Inc.
  • NanoSomiX Inc.
  • QIAGEN NV
  • Quest Diagnostics

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19511

The Global Alzheimer's Disease Biomarkers Market is projected to expand from USD 0.91 Billion in 2025 to USD 1.43 Billion by 2031, reflecting a compound annual growth rate of 7.82%. These biomarkers function as quantifiable biological indicators found in cerebrospinal fluid, blood plasma, or through imaging techniques, serving to detect pathological alterations such as amyloid beta plaques and tau protein tangles. This growth trajectory is chiefly driven by the increasing global elderly population and the urgent clinical need for early diagnosis to maximize the effectiveness of new therapeutic options. Additionally, the rapid advancement of noninvasive blood-based diagnostic solutions is broadening market reach by reducing the patient burden and procedural invasiveness typical of conventional lumbar punctures.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 0.91 Billion
Market Size 2031USD 1.43 Billion
CAGR 2026-20317.82%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

However, the market faces substantial hurdles regarding the high expense of developing diagnostic assays and the lack of consistent reimbursement coverage, which limits availability in price-sensitive areas. This economic barrier is especially concerning given the rising prevalence of the disease, which demands scalable diagnostic interventions. According to the Alzheimer's Association, an estimated 7.2 million Americans aged 65 and older are expected to be living with Alzheimer's dementia in 2025. This increasing incidence highlights a critical industry need for cost-effective and accessible biomarker platforms to ensure timely patient care and management.

Market Driver

The proliferation of disease-modifying therapies (DMTs) is fundamentally transforming the market by requiring precise companion diagnostics to determine patient eligibility and monitor treatment. As regulatory agencies approve new monoclonal antibodies that target amyloid-beta, clinical protocols are swiftly incorporating biomarker testing to verify amyloid pathology before starting therapy. This connection elevates diagnostics from simple screening tools to essential gatekeepers for pharmaceutical access, directly increasing the volume of FDA-cleared assays. To illustrate the clinical efficacy propelling this demand, Eli Lilly and Company reported in a July 2024 'FDA Approval Press Release' that the Phase 3 TRAILBLAZER-ALZ 2 study, critical for Kisunla's approval, showed the treatment slowed clinical decline by 35% in participants with confirmed amyloid and intermediate tau pathology, necessitating diagnostic platforms capable of detecting these specific markers.

Concurrently, the swift development and commercial release of minimally invasive blood-based biomarkers are removing accessibility obstacles linked to traditional PET scans and cerebrospinal fluid analysis. The adoption of high-performance plasma assays, particularly those detecting phosphorylated tau (p-tau), facilitates affordable prescreening within primary care, effectively triaging patients for further confirmation. This technological evolution is supported by recent data; an article published in 'JAMA Neurology' by the American Medical Association in January 2024 reported that a commercial p-tau217 blood assay achieved 96% diagnostic accuracy in detecting elevated brain amyloid. Such precision encourages widespread adoption, which is crucial given the high financial impact of the condition; the Alzheimer's Association projected that the total national cost for caring for individuals with Alzheimer's and other dementias would reach $360 billion in 2024.

Market Challenge

The growth of the market is primarily hindered by the substantial costs associated with developing diagnostic assays combined with inconsistent reimbursement policies. Manufacturers must invest heavily to validate and manufacture these tests, leading to premium pricing that limits access for numerous healthcare providers and patients. When insurance payers do not offer standardized or sufficient coverage, the financial responsibility falls on the individual or the medical facility. This economic uncertainty creates reluctance within healthcare systems to establish biomarker testing as a routine standard of care, thereby restricting testing volumes and stalling revenue growth for market participants.

This financial strain is especially significant within the broader economic landscape of dementia care, where resources are predominantly directed toward long-term management rather than diagnostics. The struggle for limited healthcare funding complicates the adoption of expensive diagnostic tools in the absence of guaranteed payment structures. According to the Alzheimer's Association, total estimated payments for health care, long-term care, and hospice services for people aged 65 and older with dementia were $360 billion in 2024. This immense existing expenditure on care delivery consumes available budgets, leaving little room for adopting new diagnostic technologies and directly limiting the scalability of the biomarkers market.

Market Trends

The integration of Artificial Intelligence (AI) into biomarker discovery is revolutionizing the market by facilitating the detection of new pathological signatures from intricate, multi-modal datasets. In contrast to traditional single-assay validation, AI algorithms possess the capacity to analyze immense collections of genomic, proteomic, and imaging data to identify subtle, non-linear patterns that exist before clinical symptoms appear. This ability hastens the creation of precision diagnostics by revealing latent biological factors correlated with disease progression, which improves patient stratification for clinical trials. Underscoring the promise of this technological convergence, Premier Science reported in January 2025, within the article 'Revolutionizing Alzheimer's Diagnostics: AI Tool Shows Superior Accuracy Over Traditional Methods', that a novel AI model attained nearly 90% prediction accuracy on independent datasets by recognizing latent metabolic and physiological factors linked to cognitive decline.

At the same time, the rise of digital biomarkers for remote monitoring is establishing a new standard for scalable and accessible patient assessment. This trend shifts diagnostic data capture from invasive clinical settings to continuous, non-intrusive collection utilizing consumer-grade sensors and specialized peripherals to monitor oculomotor, vocal, and behavioral metrics. These digital instruments are especially beneficial for detecting preclinical neurodegenerative changes often missed by episodic clinical examinations, presenting a cost-efficient method for mass population screening. Highlighting the precision of these non-invasive approaches, the University of Strathclyde announced in October 2025 regarding the 'ViewMind Atlas' system that the platform's integration of eye-tracking technology with machine learning analysis achieved a 96% accuracy rate in detecting asymptomatic carriers of a genetic mutation associated with Alzheimer's disease.

Key Market Players

  • Enzo Life Sciences Inc.
  • Thermo Fisher Scientific Inc.
  • AnaSpec Inc.
  • Merck KGaA
  • Cell Signaling Technology Inc.
  • Fujirebio Diagnostics Inc
  • 23andMe Inc.
  • NanoSomiX Inc.
  • QIAGEN NV
  • Quest Diagnostics

Report Scope

In this report, the Global Alzheimer's Disease Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alzheimer's Disease Biomarkers Market, By Type

  • CSF Biomarkers
  • Amyloid Beta
  • Tau Protein
  • Genetic Biomarkers
  • Apolipoprotein E
  • Blood Biomarkers
  • Others

Alzheimer's Disease Biomarkers Market, By Detection Technique

  • Molecular Diagnostics
  • Immunoassays

Alzheimer's Disease Biomarkers Market, By End user

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others

Alzheimer's Disease Biomarkers Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alzheimer's Disease Biomarkers Market.

Available Customizations:

Global Alzheimer's Disease Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alzheimer's Disease Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (CSF Biomarkers, Amyloid Beta, Tau Protein, Genetic Biomarkers, Apolipoprotein E, Blood Biomarkers, Others)
    • 5.2.2. By Detection Technique (Molecular Diagnostics, Immunoassays)
    • 5.2.3. By End user (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Alzheimer's Disease Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Detection Technique
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Alzheimer's Disease Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Detection Technique
        • 6.3.1.2.3. By End user
    • 6.3.2. Canada Alzheimer's Disease Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Detection Technique
        • 6.3.2.2.3. By End user
    • 6.3.3. Mexico Alzheimer's Disease Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Detection Technique
        • 6.3.3.2.3. By End user

7. Europe Alzheimer's Disease Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Detection Technique
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Alzheimer's Disease Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Detection Technique
        • 7.3.1.2.3. By End user
    • 7.3.2. France Alzheimer's Disease Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Detection Technique
        • 7.3.2.2.3. By End user
    • 7.3.3. United Kingdom Alzheimer's Disease Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Detection Technique
        • 7.3.3.2.3. By End user
    • 7.3.4. Italy Alzheimer's Disease Biomarkers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Detection Technique
        • 7.3.4.2.3. By End user
    • 7.3.5. Spain Alzheimer's Disease Biomarkers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Detection Technique
        • 7.3.5.2.3. By End user

8. Asia Pacific Alzheimer's Disease Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Detection Technique
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Alzheimer's Disease Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Detection Technique
        • 8.3.1.2.3. By End user
    • 8.3.2. India Alzheimer's Disease Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Detection Technique
        • 8.3.2.2.3. By End user
    • 8.3.3. Japan Alzheimer's Disease Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Detection Technique
        • 8.3.3.2.3. By End user
    • 8.3.4. South Korea Alzheimer's Disease Biomarkers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Detection Technique
        • 8.3.4.2.3. By End user
    • 8.3.5. Australia Alzheimer's Disease Biomarkers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Detection Technique
        • 8.3.5.2.3. By End user

9. Middle East & Africa Alzheimer's Disease Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Detection Technique
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Alzheimer's Disease Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Detection Technique
        • 9.3.1.2.3. By End user
    • 9.3.2. UAE Alzheimer's Disease Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Detection Technique
        • 9.3.2.2.3. By End user
    • 9.3.3. South Africa Alzheimer's Disease Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Detection Technique
        • 9.3.3.2.3. By End user

10. South America Alzheimer's Disease Biomarkers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Detection Technique
    • 10.2.3. By End user
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Alzheimer's Disease Biomarkers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Detection Technique
        • 10.3.1.2.3. By End user
    • 10.3.2. Colombia Alzheimer's Disease Biomarkers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Detection Technique
        • 10.3.2.2.3. By End user
    • 10.3.3. Argentina Alzheimer's Disease Biomarkers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Detection Technique
        • 10.3.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Alzheimer's Disease Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Enzo Life Sciences Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific Inc.
  • 15.3. AnaSpec Inc.
  • 15.4. Merck KGaA
  • 15.5. Cell Signaling Technology Inc.
  • 15.6. Fujirebio Diagnostics Inc
  • 15.7. 23andMe Inc.
  • 15.8. NanoSomiX Inc.
  • 15.9. QIAGEN NV
  • 15.10. Quest Diagnostics

16. Strategic Recommendations

17. About Us & Disclaimer